Staff Reports
President Donald Trump announced on his Truth Social account that the University of Miami “gave” its original 1994 ibogaine Investigational New Drug (IND) application to the federal government. The White House has been pushing psychedelic therapy forward all year, but this particular claim — a supposedly historic handoff — deserves a closer look. As conservatives who back veterans and common-sense rule of law, we should cheer progress but insist on receipts and proper procedure.
The announcement and what it would mean
The President framed the alleged transfer as a game-changer that will let the federal government access the “foundational FDA authorization” for ibogaine and speed treatment options for veterans. There’s real history behind the claim: University of Miami researchers did file ibogaine IND work in the early 1990s, and that record is part of why the administration is pushing psychedelics. Still, an offhand post does not replace a formal agency or university confirmation. Right now, there’s no HHS or FDA press release and no public University of Miami statement proving the transfer actually happened.
Regulatory reality: an IND is not just a trophy
An IND is a formal file with legal obligations and a paper trail. In plain language: you don’t “gift” an IND like a pennant at a ballgame. Federal rules require written notice and agency acknowledgment to change sponsorship or custody of an IND. If the University of Miami really handed over that 1994 file, we should see an FDA record number, a university memo, or at least a clear HHS acknowledgement. With an acting FDA head in place and HHS Secretary Robert F. Kennedy Jr. heavily involved in the administration’s push, there’s every reason the agencies would make the transfer public — if it actually happened.
Why conservatives should care: veterans, safety, and oversight
There are two good reasons to support careful expansion of psychedelic research: it could help veterans with PTSD and addiction, and it could reduce needless suffering. Recent academic work — including neuroimaging studies of veteran cohorts — shows promise for ibogaine when monitored properly. But the drug has known cardiac risks and needs strict medical oversight. Conservatives who care about our troops and taxpayer accountability should want faster science, yes, but not a free-for-all where safety rules are waved away for headlines. Speed is welcome; sloppy paperwork is not.
What comes next — demand the receipts
If this transfer is real, University of Miami, HHS, and the FDA should produce the documents and explain the chain of custody. If it isn’t real, the President’s claim risks undermining confidence in an important policy push. Either way, Congress and the media should press for transparency so progress is built on facts, not fog. We can back bold treatments for veterans and encourage innovation — and still insist the government follow the rules and show the evidence. That’s how you win both results and respect.
